Last edition
News about "active pharmaceutical ingredient "
IOL Chemicals and Pharmaceuticals Reports Q3 and 9M FY26 Results
IOL Chemicals and Pharmaceuticals reported strong Q3 and nine-month FY26 results, with profit before exceptional items rising 39 percent year-on-year, supported by margin expansion and improved operational performance.
Active Pharmaceutical Ingredient | 12/02/2026 | By News Bureau | 142
PharmAla Biotech Australia Ties Up with UK CDMO to Manufacture ALA-002
PharmAla Biotech Australia has contracted a UK-based CDMO to manufacture the drug substance for ALA-002, its patented non-racemic MDMA formulation, ahead of planned phase 2a/2b clinical trials for social anxiety disorder expected to begin in 2026.
Active Pharmaceutical Ingredient | 16/12/2025 | By News Bureau | 191
Eli Lilly Expands USA Manufacturing with Alabama Plant
The site will focus on producing synthetic and peptide-based medicines, including Lilly’s first oral GLP-1 weight-loss therapy, Orforglipron, which the company expects to submit for regulatory approval early next year.
Active Pharmaceutical Ingredient | 11/12/2025 | By Darshana | 135
Sai Life Sciences Completes Phase-II of Production Block 11 at Bidar site
Sai Life Sciences’ Unit IV in Bidar is the company’s flagship manufacturing site, specialising in the production of APIs and advanced intermediates for markets such as the US, EU and Japan.
Active Pharmaceutical Ingredient | 29/08/2025 | By Dineshwori | 409
Torrent Pharma's Vizag API Unit Passes USFDA Inspection with Zero Observation
The US Food and Drug Administration (USFDA) has completed the inspection of Torrent Pharma's API manufacturing facility located in Vizag, Andhra Pradesh.
Active Pharmaceutical Ingredient | 04/08/2025 | By Dineshwori | 865
Monitor NDMA Impurity in Ranitidine Formulation: DCGI Directs Indian Drugmakers
The DCGI has instructed drug controllers of all States and Union Territories to ensure that manufacturers under their jurisdiction monitor the presence of N-Nitrosodimethylamine(NDMA) - a potentially carcinogenic impurity – in the active pharmaceutical ingredient (API) and formulation of the antacid Ranitidine.
Active Pharmaceutical Ingredient | 31/07/2025 | By Dineshwori | 1146
SK pharmteco Unveils State-of-the-Art HPAPI Laboratory
Designed for the safe handling of potent chemicals for CGMP testing and release, the lab is now fully operational and has already achieved a significant milestone: the successful release of its first Active Pharmaceutical Ingredient (API).
Active Pharmaceutical Ingredient | 15/02/2025 | By Aishwarya | 449
Lilly Signs Deal with EVA Pharma to Expand Access to baricitinib
This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030.
Active Pharmaceutical Ingredient | 05/09/2024 | By Aishwarya | 605
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy